Medical News

Bezafibrate Improves Glucose Uptake and Endothelial Function in HIV Patient

March 28, 2003

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

A study from Sweden has found that an HIV-positive patient with lipodystrophy syndrome showed a decline in serum triglycerides along with a significant improvement in glucose uptake following treatment with the drug bezafibrate for three months. "This improvement may be a consequence of the Randle effect, i.e. increased availability of plasma-free fatty acids is negatively correlated to glucose uptake. We also noted a significant improvement in endothelial-dependent flow-mediated dilatation after treatment with bezafibrate. This effect could result from the increased glucose uptake observed and a decrease in insulin resistance secondary to the lowered triglyceride levels by bezafibrate," according to Thomas Nystrom and colleagues at South Stockholm Hospital.

The researchers concluded that, "bezafibrate may be of clinical utility in the lipodystrophy syndrome, through its beneficial effects on insulin resistance, glucose uptake and endothelial dysfunction." The study, "Bezafibrate-Induced Improvement in Glucose Uptake and Endothelial Function in Protease Inhibitor-Associated Insulin Resistance," appeared in the Journal of Internal Medicine (2002;252(6):570-574).

Back to other CDC news for March 28, 2003

Previous Updates

Adapted from:
Drug Week

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.